ABSTRACT
Background We present the data from an open-label study involved in the selection of optimum formulation of RBD-based protein sub-unit COVID-19 vaccine.
Methods The randomized Phase-1/2 trial followed by a Phase-2 trial was carried out to assess safety and immunogenicity of different formulation of COVID-19 vaccine (Corbevax) and select an optimum formulation for a phase 3 study. Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection, were enrolled.
Findings Low incidence of adverse events were reported post-vaccination of different Corbevax formulations and majority were mild in nature and no Grade-3 or serious adverse events were observed. All formulations in Phase-1/2 study showed similar profile of humoral and cellular immune-response with higher response associated with increasing CpG1018 adjuvant content at same RBD protein content. Hence, high concentration of CpG1018 was tested in phase-2 study, which showed significant improvement in immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, nAb-titers and cellular immune-responses while maintaining the safety profile. Interestingly, binding and neutralizing antibody titers were persisted consistently till 6 months post second vaccine dose.
Interpretations Corbevax was well tolerated with no observed safety concerns. Neutralizing antibody titers were suggestive of high vaccine effectiveness compared with human convalescent plasma or protective thresholds observed during vaccine efficacy trials of other COVID-19 vaccines. The study was prospectively registered with clinical trial registry of India-CTRI/2021/06/034014 and CTRI/2020/11/029032.
Funding Bill & Melinda Gates Foundation, BIRAC-division of Department of Biotechnology, Govt of India, and the Coalition for Epidemic Preparedness Innovations funded the study.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2021/06/034014 and CTRI/2020/11/029032
Funding Statement
The Bill & Melinda Gates Foundation, the BIRAC- a division of the Department of Biotechnology, Govt of India, and the Coalition for Epidemic Preparedness Innovations funded the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Investigational Review Board or Ethics Committee at each study site approved the protocol. Institutional Ethics Committees (IECs) of 5 study sites for phase-1/2 (BECT062) study 1. St. Theresas Hospital- Hyderabad- Approved on 10/11/2020 2. Guru Teg Bahadur Hospital Ethics Committee- Delhi- Approved on 28/11/2020 3. All India Institute of Medical Sciences- Patna- Approved on 06/11/2020 4. Maharaja Agrasen Hospital- Approved on 25/12/2020 5. King George Hospital- Visakhapatnam- Approved on 12/11/2020 Institutional Ethics Committees (IECs) of 7 study sites for phase-2 (BECT069) study 1. St. Theresas Hospital- Approved on 07/06/2021 2. Guru Teg Bahadur Hospital Ethics Committee- Approved on 03/06/2021 3. ESIC Medical College and Hospital- Approved on 08/06/2021 4. Prakhar Hospital Pvt Ltd- Approved on 04/06/2021 5. All India Institute of Medical Sciences- Patna- Approved on 09/06/2021 6. Maharaja Agrasen Hospital- Approved on 06/06/2021 7. AIG Hospital- Approved on 15/06/2021
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Additional study data which is not part of the manuscript can be made available upon request and addressed to the corresponding author Dr. Subhash Thuluva at his email subhash.thuluva@biologicale.com.
